Jc. Schwartz et al., FUNCTIONAL IMPLICATIONS OF MULTIPLE DOPAMINE-RECEPTOR SUBTYPES - THE D-1 D-3 RECEPTOR COEXISTENCE/, Brain research reviews, 26(2-3), 1998, pp. 236-242
The D-3 dopamine receptor, a D-2-like receptor, is selectively express
ed in the ventral striatum, particularly in the shell of nucleus accum
bens and islands of Calleja, where it is found in medium sized substan
ce P neurons. The latter co-express the D-1 receptor whose interaction
with the D-3 receptor was studied by treating rats with selective ago
nists and antagonists. In agreement with the opposite cAMP response, t
hey mediate in cultured neuroblastoma cells, the D-1 and D-3 receptors
exerted opposite influences on c-fos expression in islands of Calleja
. However, in agreement with the synergistic influence of cAMP on D-3
receptor-mediated mitogenesis on the same cultured cells, D-1 and D-3
receptor stimulation in vivo synergistically enhanced preprotachykinin
mRNA in the shell of accumbens. This indicates that the two receptor
subtypes may affect neurons in either synergy or opposition according
to the cell or signal generated. Levodopa-induced behavioral sensitiza
tion in hemiparkinsonian rats is another example of D-1/D-3 receptor i
nteraction. Hence repeated levodopa administration induces the ectopic
appearance of the D-3 receptor in substance P/dynorphin, striatonigra
l neurons of the dorsal striatum. This induction is secondary to D-1 r
eceptor stimulation in neurons of the denervated side and fully accoun
ts for the sensitization, i.e. the increased behavioral responsiveness
to levodopa. During brain development, a similar process could operat
e to control the late appearance of the D-3 receptor in D-1-receptor b
earing neurons of the ventral striatum at a time at which they start t
o be innervated by dopamine neurons. Finally, taking into account a va
riety of genetic, developmental, neuroimaging and pharmacological data
, we postulate that imbalances between the levels of DI and Dg recepto
rs in the same neurons could be responsible for schizophrenic disorder
s. (C) 1998 Elsevier Science B.V. All rights reserved.